Does the media favor NRC or SDGR?

In the previous week, Schrodinger had 3 more articles in the media than National Research. MarketBeat recorded 5 mentions for Schrodinger and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat Schrodinger's score of 1.05 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Schrodinger 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CERT or NRC?

In the previous week, Certara and Certara both had 2 articles in the media. Certara's average media sentiment score of 1.37 beat National Research's score of 1.31 indicating that Certara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Certara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NRC or GDRX?

GoodRx has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio National Research $137.39M 3.50 $11.60M $0.25 84.48 GoodRx $796.85M 1.46 $30.44M $0.04 84.75

Does the media prefer NRC or GDRX?

In the previous week, GoodRx had 1 more articles in the media than National Research. MarketBeat recorded 3 mentions for GoodRx and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat GoodRx's score of 1.08 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GoodRx 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TDOC or NRC?

In the previous week, Teladoc Health had 4 more articles in the media than National Research. MarketBeat recorded 6 mentions for Teladoc Health and 2 mentions for National Research. Teladoc Health's average media sentiment score of 1.40 beat National Research's score of 1.31 indicating that Teladoc Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teladoc Health 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NRC or HSTM?

In the previous week, HealthStream had 2 more articles in the media than National Research. MarketBeat recorded 4 mentions for HealthStream and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat HealthStream's score of 1.27 indicating that National Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment National Research 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HealthStream 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

National Research (NRC) Competitors

$21.12 -0.14 (-0.66%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$21.16 +0.04 (+0.17%)

As of 09/11/2026 07:30 PM Eastern

Compare

NRC vs. SDGR, CERT, GDRX, TDOC, and HSTM

Should you buy National Research stock or one of its competitors? National Research's main competitors and comparable companies include Schrodinger (SDGR), Certara (CERT), GoodRx (GDRX), Teladoc Health (TDOC), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does National Research compare to Schrodinger?

National Research (NASDAQ:NRC) and Schrodinger (NASDAQ:SDGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

National Research currently has a consensus target price of $26.00, suggesting a potential upside of 23.11%. Schrodinger has a consensus target price of $20.50, suggesting a potential upside of 7.78%. Given National Research's stronger consensus rating and higher probable upside, research analysts plainly believe National Research is more favorable than Schrodinger.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Schrodinger	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

47.3% of National Research shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 9.2% of National Research shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Schrodinger had 3 more articles in the media than National Research. MarketBeat recorded 5 mentions for Schrodinger and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat Schrodinger's score of 1.05 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Schrodinger	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

National Research has a net margin of 4.18% compared to Schrodinger's net margin of -20.98%. National Research's return on equity of 164.26% beat Schrodinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
Schrodinger	-20.98%	-16.37%	-8.19%

National Research has higher earnings, but lower revenue than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.50	$11.60M	$0.25	84.48
Schrodinger	$255.87M	5.49	-$103.26M	-$0.74	N/A

National Research has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Schrodinger has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Summary

National Research beats Schrodinger on 8 of the 15 factors compared between the two stocks.

How does National Research compare to Certara?

Certara (NASDAQ:CERT) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Certara and Certara both had 2 articles in the media. Certara's average media sentiment score of 1.37 beat National Research's score of 1.31 indicating that Certara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Certara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Certara has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, National Research has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

74.0% of Certara shares are held by institutional investors. Comparatively, 47.3% of National Research shares are held by institutional investors. 1.1% of Certara shares are held by company insiders. Comparatively, 9.2% of National Research shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Certara currently has a consensus target price of $8.28, suggesting a potential upside of 9.64%. National Research has a consensus target price of $26.00, suggesting a potential upside of 23.11%. Given National Research's stronger consensus rating and higher possible upside, analysts plainly believe National Research is more favorable than Certara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Certara	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.45
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

National Research has a net margin of 4.18% compared to Certara's net margin of -16.75%. National Research's return on equity of 164.26% beat Certara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Certara	-16.75%	3.86%	2.65%
National Research	4.18%	164.26%	14.67%

National Research has lower revenue, but higher earnings than Certara. Certara is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Certara	$418.84M	2.75	-$1.60M	-$0.45	N/A
National Research	$137.39M	3.50	$11.60M	$0.25	84.48

Summary

National Research beats Certara on 10 of the 16 factors compared between the two stocks.

How does National Research compare to GoodRx?

National Research (NASDAQ:NRC) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

National Research has a net margin of 4.18% compared to GoodRx's net margin of 2.07%. National Research's return on equity of 164.26% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
GoodRx	2.07%	7.22%	2.53%

47.3% of National Research shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 9.2% of National Research shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

National Research presently has a consensus price target of $26.00, indicating a potential upside of 23.11%. GoodRx has a consensus price target of $4.23, indicating a potential upside of 24.70%. Given GoodRx's higher probable upside, analysts plainly believe GoodRx is more favorable than National Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
GoodRx	3 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.08

In the previous week, GoodRx had 1 more articles in the media than National Research. MarketBeat recorded 3 mentions for GoodRx and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat GoodRx's score of 1.08 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GoodRx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

GoodRx has higher revenue and earnings than National Research. National Research is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.50	$11.60M	$0.25	84.48
GoodRx	$796.85M	1.46	$30.44M	$0.04	84.75

National Research has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, GoodRx has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

Summary

National Research beats GoodRx on 9 of the 16 factors compared between the two stocks.

How does National Research compare to Teladoc Health?

Teladoc Health (NYSE:TDOC) and National Research (NASDAQ:NRC) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Teladoc Health has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, National Research has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Teladoc Health currently has a consensus target price of $7.54, indicating a potential upside of 22.37%. National Research has a consensus target price of $26.00, indicating a potential upside of 23.11%. Given National Research's stronger consensus rating and higher possible upside, analysts clearly believe National Research is more favorable than Teladoc Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teladoc Health	1 Sell rating(s)	10 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.25
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

National Research has a net margin of 4.18% compared to Teladoc Health's net margin of -7.13%. National Research's return on equity of 164.26% beat Teladoc Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teladoc Health	-7.13%	-12.15%	-5.83%
National Research	4.18%	164.26%	14.67%

National Research has lower revenue, but higher earnings than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teladoc Health	$2.53B	0.44	-$200.32M	-$0.99	N/A
National Research	$137.39M	3.50	$11.60M	$0.25	84.48

76.8% of Teladoc Health shares are owned by institutional investors. Comparatively, 47.3% of National Research shares are owned by institutional investors. 0.7% of Teladoc Health shares are owned by insiders. Comparatively, 9.2% of National Research shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Teladoc Health had 4 more articles in the media than National Research. MarketBeat recorded 6 mentions for Teladoc Health and 2 mentions for National Research. Teladoc Health's average media sentiment score of 1.40 beat National Research's score of 1.31 indicating that Teladoc Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teladoc Health	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

National Research beats Teladoc Health on 10 of the 16 factors compared between the two stocks.

How does National Research compare to HealthStream?

National Research (NASDAQ:NRC) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

HealthStream has a net margin of 6.60% compared to National Research's net margin of 4.18%. National Research's return on equity of 164.26% beat HealthStream's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
National Research	4.18%	164.26%	14.67%
HealthStream	6.60%	6.81%	4.64%

National Research currently has a consensus target price of $26.00, indicating a potential upside of 23.11%. HealthStream has a consensus target price of $27.00, indicating a potential downside of 7.25%. Given National Research's stronger consensus rating and higher possible upside, analysts clearly believe National Research is more favorable than HealthStream.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
National Research	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
HealthStream	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

National Research has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, HealthStream has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market.

HealthStream has higher revenue and earnings than National Research. HealthStream is trading at a lower price-to-earnings ratio than National Research, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
National Research	$137.39M	3.50	$11.60M	$0.25	84.48
HealthStream	$304.06M	2.80	$18.34M	$0.72	40.43

In the previous week, HealthStream had 2 more articles in the media than National Research. MarketBeat recorded 4 mentions for HealthStream and 2 mentions for National Research. National Research's average media sentiment score of 1.31 beat HealthStream's score of 1.27 indicating that National Research is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
National Research	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HealthStream	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.3% of National Research shares are owned by institutional investors. Comparatively, 69.6% of HealthStream shares are owned by institutional investors. 9.2% of National Research shares are owned by insiders. Comparatively, 20.4% of HealthStream shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

National Research pays an annual dividend of $0.64 per share and has a dividend yield of 3.0%. HealthStream pays an annual dividend of $0.14 per share and has a dividend yield of 0.5%. National Research pays out 256.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. HealthStream pays out 19.4% of its earnings in the form of a dividend. HealthStream has increased its dividend for 2 consecutive years.

Summary

HealthStream beats National Research on 10 of the 19 factors compared between the two stocks.

Get National Research News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRC vs. The Competition

Export

Metric	National Research	Healthcare Technology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$480.40M	$1.69B	$7.12B	$12.72B
Dividend Yield	3.03%	4.69%	2.56%	11.15%
P/E Ratio	84.48	20.39	275.24	25.29
Price / Sales	3.50	87.95	655.99	98.94
Price / Cash	16.80	31.50	77.04	51.44
Price / Book	34.06	5.96	10.33	6.20
Net Income	$11.60M	-$18.66M	$3.50B	$358.50M
7 Day Performance	-1.90%	-1.52%	-3.32%	-2.35%
1 Month Performance	2.47%	3.60%	-0.41%	-2.77%
1 Year Performance	31.92%	-14.71%	19.21%	7.63%

National Research Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRC National Research	2.9421 of 5 stars	$21.12 -0.7%	$26.00 +23.1%	+30.4%	$480.40M	$137.39M	84.48	490	Positive News
SDGR Schrodinger	1.4602 of 5 stars	$20.84 +6.9%	$20.50 -1.6%	+1.3%	$1.44B	$255.87M	N/A	790	Positive News Gap Up
CERT Certara	1.5766 of 5 stars	$8.10 -2.3%	$8.28 +2.2%	-30.9%	$1.26B	$418.84M	N/A	1,576
GDRX GoodRx	4.7725 of 5 stars	$3.46 -0.9%	$4.23 +22.2%	-19.7%	$1.20B	$796.85M	86.52	950
TDOC Teladoc Health	2.7449 of 5 stars	$6.25 -1.4%	$7.54 +20.6%	-20.7%	$1.15B	$2.53B	N/A	5,600	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRC) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

National Research (NRC) Competitors

NRC vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does National Research compare to Schrodinger?

Summary

How does National Research compare to Certara?

Summary

How does National Research compare to GoodRx?

Summary

How does National Research compare to Teladoc Health?

Summary

How does National Research compare to HealthStream?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

National Research (NRC) Competitors

NRC vs. SDGR, CERT, GDRX, TDOC, and HSTM

How does National Research compare to Schrodinger?

Do analysts recommend NRC or SDGR?

Do insiders & institutionals believe in NRC or SDGR?

Does the media favor NRC or SDGR?

Is NRC or SDGR more profitable?

Which has higher earnings & valuation, NRC or SDGR?

Which has more risk and volatility, NRC or SDGR?

Summary

How does National Research compare to Certara?

Does the media favor CERT or NRC?

Which has more risk & volatility, CERT or NRC?

Do insiders & institutionals believe in CERT or NRC?

Do analysts recommend CERT or NRC?

Is CERT or NRC more profitable?

Which has better earnings and valuation, CERT or NRC?

Summary

How does National Research compare to GoodRx?

Is NRC or GDRX more profitable?

Do institutionals and insiders have more ownership in NRC or GDRX?

Do analysts prefer NRC or GDRX?

Does the media prefer NRC or GDRX?

Which has stronger earnings & valuation, NRC or GDRX?

Which has more volatility & risk, NRC or GDRX?

Summary

How does National Research compare to Teladoc Health?

Which has more risk & volatility, TDOC or NRC?

Do analysts rate TDOC or NRC?

Is TDOC or NRC more profitable?

Which has higher valuation and earnings, TDOC or NRC?

Do insiders and institutionals have more ownership in TDOC or NRC?

Does the media favor TDOC or NRC?

Summary

How does National Research compare to HealthStream?

Is NRC or HSTM more profitable?

Do analysts rate NRC or HSTM?

Which has more volatility and risk, NRC or HSTM?

Which has preferable valuation and earnings, NRC or HSTM?

Does the media prefer NRC or HSTM?

Do insiders and institutionals have more ownership in NRC or HSTM?

Is NRC or HSTM a better dividend stock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRC vs. The Competition

National Research Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools